Flexion Therapeutics Inc. looked to move Zilretta (FX006) over the goal line after a damaging pivotal phase IIb miss in late 2015 by reporting findings from an initial phase III showing that the injected intra-articular (IA) sustained-release, non-opioid, non-steroid treatment achieved clinically meaningful and highly statistically significant separation from placebo in treating moderate to severe osteoarthritis (OA) knee pain at each measured time point in weeks one through 16, meeting the primary endpoint at week 12 with a "p" value of